Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy
暂无分享,去创建一个
Tomasz P. Michalak | N. Terrault | C. Coffin | J. Roberts | P. M. Mulrooney-Cousins | T. Michalak | G. van Marle | John P Roberts | Norah A Terrault | Carla S Coffin | Patricia M Mulrooney-Cousins | Guido van Marle | Tomasz I Michalak
[1] J. Roberts,et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy , 2011, Journal of viral hepatitis.
[2] D. Samuel,et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. , 1997, Journal of hepatology.
[3] T. Michalak,et al. In Vitro and In Vivo Infectivity and Pathogenicity of the Lymphoid Cell-Derived Woodchuck Hepatitis Virus , 2001, Journal of Virology.
[4] Tomasz P. Michalak,et al. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. , 1999, The Journal of clinical investigation.
[5] J. Jang,et al. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine‐resistant hepatitis B virus during adefovir therapy , 2007, Journal of medical virology.
[6] S. Papson,et al. “Model” , 1981 .
[7] S. Locarnini. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance , 1998, Hepatology.
[8] Tomasz P. Michalak,et al. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection , 2004, Hepatology.
[9] M. Manns,et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. , 2001, Journal of hepatology.
[10] C. Coffin,et al. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. , 2004, Journal of virology.
[11] Ding‐Shinn Chen,et al. Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases , 2010, Journal of Virology.
[12] F. Zoulim,et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. , 2009, Gastroenterology.
[13] M. Rizzetto,et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[14] T. Liang,et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[15] A. Lok,et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[16] Tomasz P. Michalak,et al. Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[17] M. Ciotti,et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. , 2011, Journal of hepatology.
[18] Mark J. Thomas,et al. Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin , 2007, Digestive Diseases and Sciences.
[19] Nidhi Singh,et al. Management of hepatitis B virus. , 2008, The Journal of antimicrobial chemotherapy.
[20] S. Locarnini. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure , 2008, Hepatology international.
[21] K. Man,et al. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[22] G. Alexander,et al. Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.
[23] D. Samuel,et al. HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.
[24] P. Coursaget,et al. Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes , 2004, Intervirology.
[25] N. Terrault,et al. Hepatitis B immune globulin preparations and use in liver transplantation. , 2003, Clinics in liver disease.
[26] D. Samuel,et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. , 1990, Transplantation.
[27] M. Buti,et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. , 2003, Journal of hepatology.
[28] S. Gujar,et al. Primary Occult Hepadnavirus Infection Induces Virus-Specific T-Cell and Aberrant Cytokine Responses in the Absence of Antiviral Antibody Reactivity in the Woodchuck Model of Hepatitis B Virus Infection , 2009, Journal of Virology.
[29] D. Samuel,et al. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.